Plexxikon
American drug discovery company
From Wikipedia, the free encyclopedia
Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Founder | Joseph Schlessinger |
| Defunct | 2011 |
| Fate | Acquired by the Daiichi Sankyo |
| Headquarters | South San Francisco, California, United States. |
| Website | www |
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[citation needed][1]
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2][3][4]
Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]
Drug pipeline
- Vemurafenib (Zelboraf) and pexidartinib (Turalio) are two FDA approved drugs developed by Plexxikon
- Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[6] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[7]